Uveitis is a chronic disease characterized by intraocular inflammation. It mainly affects people of working age and leads to blindness and disability. The aim of the present study was to provide a systematic review of the literature data on quality of life in patients with uveitis. Material and methods: For the period 1996-2021, in the available databases (PubMed, BioMedCentral, ScienceDirect, Scopus, Web of Science) a systematic analysis of scientific publications examining the assessment of quality of life in patients with uveitis was performed. Results: 5,238 publications were found for the study period, of which 1,141 were reviews and 1,647 were articles with research results. In developed countries, uveitis is the second leading cause of diabetic retinopathy of blindness in people between the ages of 20 and 65, representing up to 10% of cases of registered blindness. Over 50% of people with uveitis will develop complications related to the disease, and over 30% will have visual impairment. As a result, uveitis is associated with economic, social and personal burden, leading to incapacity for work, reduced productivity at work or at home, and job loss, which threatens the employment and financial well-being of patients. Conclusion: The quality of life in patients with uveitis is closely related to visual impairment (anterior and posterior uveitis) and pain syndrome (anterior uveitis). Uveitis is a disease that is most often chronic with a different period of time of manifestations of the disease, which requires constant monitoring.
Йорданов Й, Златарова З, Ненчева Б, Стойчева З. Оценка на качеството на живот при болни с първична откритоъгълна глаукома. Глаукоми, 2018, 7(1), 5-14.
Йорданов Й, Ненчева Б, Стойчева З. Kaчество на живот при пациенти с първична откритоъгълна глаукома. Варненски медицински форум, 2018, 7(1), 45-48.
Йорданов Й, Ненчева Б, Стойчева З. Качество на живот при пациенти с първична откритоъгълна глаукома в зависимост от проведеното лечение. Варненски медицински форум, 2018, 7(1), 49-52.
Adán-Civera AM, Benítez-del-Castillo JM, Blanco-Alonso R, et al. Carga y costes directos de la uveítis no infecciosa en España. Reumatol Clín, 2015.
Angeles-Han ST. Quality of life metrics in pediatric uveitis. Int Opthalmol Clin, 2015;55(2):93-101.
Bradley E A, Bradley D, Bartley GB. Evaluating healthrelated quality of life in ophthalmic disease: Practical considerations. Arch Ophthalmol, 2006;124:121-122.
Braithwaite T, Calvert M, Gray M et al. The use of patient-reported outcome research in modern ophthalmology: impact on clinical trials and routine clinical practice. Patient Relat Outcome Meas, 2019;10:9-24.
Chang JH-M, Wakefield D. Uveitis: A global perspective. Ocul Immunol Inflamm, 2002;10:263-279.
De Smet MD, Taylor SR, Bodaghi B et al. Understanding uveitis: the impact of research on visual outcomes. Prog Retin Eye Res, 2011;30:452-70.
Dean S, Mathers JM, Calvert M et al. The patient is speaking: discovering the patient voice in ophthalmology. Br J Ophthalmol, 2017;101:700-8.
Denniston AK, Kyte D, Calvert M et al. An introduction to patient-reported outcome measures in ophthalmic research. Eye (Lond), 2014;28:637-45.
Denniston AK, Holland GN, Kidess A et al. Heterogeneity of primary outcome measures used in clinical trials of treatments for intermediate, posterior, and panuveitis. Orphanet J Rare Dis, 2015;10:97.
Durrani OM, Meads CA, Murray PI. Uveitis: A potentially blinding disease. Ophthalmologica, 2004;218:223-236.
Frick KD, Drye LT, Kempen JH et al. Associations among visual acuity and visionand health-related quality of life among patients in the multicenter uveitis steroid treatment trial. Invest Ophthalmol Vis Sci, 2012;53:1169-76.
Gardiner AM, Armstrong RA, Dunne MCM et al. Correlation between visual function and visual ability in patients with uveitis. Br J Ophthalmol, 2002;86:993-996.
Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California: The Northern California Epidemiology of Uveitis Study. Ophthalmology, 2004;111:491-500.
Gui W, Dombrow M, Marcus I et al. Quality of life in patients with noninfectious uveitis treated with or without systemic anti-inflammatory therapy. Ocul Immunol Inflamm, 2015;23:135-143.
Hariprasad SM, Joseph G, Gagnon-Sanschagrin P et al. Healthcare costs among patients with macular oedema associated with non-infectious uveitis: a US commercial payer‘s perspective. BMJ Open Ophthalmol, 2021 Nov 10;6(1):e000896.
Hui MM, Wakefield D, Patel I et al. Visual functioning and health-related quality of life are compromised in patients with uveitis. Ocul Immunol Inflamm, 2017;25(4):486-91.
Jabs DA, Rosenbaum JT, Foster CS et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: Recommendations of an expert panel. Am J Ophthalmol, 2000;130:492-513.
Jalil A, Yin K, Coyle L et al. Visionrelated quality of life and employment status in patients with uveitis of working age: A prospective study. Ocul Immunol Inflamm, 2012;20:262-265.
Kirbach E, Hayes S, Cifaldi M. The economic burden of uveitis. Arthritis Rheum, 2010;62(Suppl10):788.
Kuiper JJW, Missotten T, Baarsma SG et al. Visionrelated quality of life in patients with birdshot chorioretinopathy. Acta Ophthalmol, 2013;91.
Lightman S, Belfort R, Naik RK et al. Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. Invest Ophthalmol Vis Sci, 2013;54:4864-70.
Mangione CM, Lee PP, Gutierrez PR et al. National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119(7):1050-8.
Miserocchi E, Modorati G, Mosconi P et al. Quality of life in patients with uveitis on chronic systemic immunosuppressive treatment. Ocul Immunol Inflamm, 2010;18:297-304.
Murphy CC, Hughes EH, Frost NA et al. Quality of life and visual function in patients with intermediate uveitis. Br J Ophthalmol, 2005;89:1161-5.
Murphy CC, Greiner K. Cyclosporine verses Tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol, 2005;123:634-41.
Murphy CC, Greiner K, Plskova J et al. Validity of using vision-related quality of life as a treatment end point in intermediate and posterior uveitis. Br J Ophthalmol, 2007;91:154-156.
Naik RK, Rentz AM, Foster CS et al. Normative comparison of patientreported outcomes in patients with noninfectious uveitis. JAMA Ophthalmol, 2013;131:219-25.
Naik RK, Gries KS, Rentz AM et al. Psychometric evaluation of the National Eye Institute Visual Function Questionnaire and Visual Function Questionnaire Utility Index in patients with non-infectious intermediate and posterior uveitis. Qual Life Res, 2013;22:2801-2808.
Park K. Park‘s Text book of Preventive and Social Medicine. 19th ed. Jabalpur: Banarasidas Bhanot Publishers, 2007. p. 16.
Rathinam SR, Sathian N. Vision and health related quality of life in immunosuppressive treated uveitic population. Tamilnadu J Ophthalmol, 2006;44:33-6.
Rothova A, Suttorp-van Schulten MS, Frits Treffers W et al. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol, 1996;80(4):332-336.
Schiffman RM, Jacobsen G, Whitcup SM. Visual functioning and general health status in patients with uveitis. Arch Ophthalmol, 2001;119(6):841-9.
Suger EA, Venugopal V, Thorne JE et al. Longitudinal vision-related quality of life for patients with non-infectious uveitis treated with fluocinolone acetonide implant or systematic corticosteroid therapy. Ophthalmology, 2017;124(11):1662-9.
Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: A literature survey. Br J Ophthalmol, 1996;80:844-848.
Tan P, Koh YT, Wong PY, Teoh SC. Evaluation of the impact of uveitis on visual-related quality of life. Ocul Immunol Inflamm, 2012;20:453-459.
Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin. 2005;45:1-13.
Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull, 2010;96:5-21.
Williams GJ, Brannan S, Forrester JV et al. The prevalence of sight-threatening uveitis in Scotland. Br J Ophthalmol, 2007;91:33-36.
Email this article (Login required) 
